Pfizer will begin to target women in its television commercials for the erectile dysfunction drug Viagra.» Read More
As we head into the holiday break and the bloggable newsflow slows to a trickle, I am digging into the overflowing mailbag while filling in for my vacationing colleague Scott Wapner at the Nasdaq this week.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Some of the bad news Tuesday was "less worse" than many feared: Goldman Sachs reported its first quarterly loss since going public — but the $2.1 billion loss was much narrower than many had feared and Goldman shares rose as much as 11 percent. Stocks soared on the Federal Reserve rate-cut decision and options trading looks bullish on Boeing. CNBC heard from experts who predict a massive OPEC cut and more Fed moves to come.
Drugmaker Bristol-Myers Squibb said Tuesday it will eliminate another 10 percent of its work force through 2010 as it works to pare costs before it loses patent protection on key drugs.
We know all too well about the victims of the market's recent misfortunes, but what about those who have survived — and even thrived? Count Tom Forester and his five-star Forester Value Fund among those.
For months now several analysts have been pointing out that despite big pharma's many problems some of the companies still pay healthy dividends. And when T-bills are offering next to nothing, a solid dividend yield in these rough and tumble times is a good thing.
Pharma companies are usually considered safety plays. But might they also be growth stocks in disguise?
Jamie Cox of Harris Financial Group is looking past the current "flight to quality" that has dropped Treasury yields so far, and saying where he thinks the money will be heading when it comes flying back.
With the market trading sideways more investors are turning to high yielding dividend stocks. But can you trust these companies to keep pumping out profits?
Fortune Magazine is looking ahead to 2009 with a list of 10 promising stocks. Senior editor Leigh Gallagher says, "When markets return, they return in force. Usually, after a bear market, in the first nine months, the market goes up by an average of 32 percent, so if you wait, you risk missing big momentum."
Five stocks, huge yields, great defense against this volatile market.
As we wait to see what Barack does in the new year, what can you do today to position your investment strategy for an Obama Administration? Here are some ideas.
Health care has been one of the best performing sectors in the S&P 500 this year. Are these stocks good for what ails you?
ExxonMobil is the largest stock in the S&P 500. Wal-Mart, the nearest competitor, is a little more than half that size. ExxonMobil has been notably outperforming the market recently. Since early September, Exxon has been up about 5 percent, while the S&P 500 has been down 30 percent.
General Electric announced that it will maintain its dividend for 2009, giving it an 8.6% yield, based on yesterday's close. See how this compares to the other 29 companies in the Dow.
Does the Food and Drug Administration approve drugs anymore? Or are we seeing the lame-duck leadership at the agency punt any action over to the next administration?
The U.S. government's plan to inject $20 billion into Citigroup failed to fully reassure analysts about financials. So what is safe to invest in now? Tim Harris at JPMorgan Asset Management and Khiem Do at Baring Asset Management offered their sector strategies to CNBC.
As the market remains focused on Citi and the President-elect's midday cabinet announcement there are a few newsworthy things going on in biopharmaland.
Health-care reform is not the only thing big pharmaceuticals have to fear, according to Deutsche Bank's Barbara Ryan. There's also the rapidly-growing dominance of generic prescription drugs. Still, she likes several big-name companies in the field.
This stock's performance is a key barometer for the market, Cramer says.